17 studies found for:    Open Studies | "Pneumococcal Infections"
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Recruiting A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax
Condition: Pneumococcal Infection
Interventions: Biological: PnuBioVax;   Biological: Placebo
2 Recruiting Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
Conditions: Pneumococcal Infection;   ANCA-associated Vasculitis
3 Recruiting Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Conditions: Pneumococcal Infection;   ANCA-associated Vasculitis
4 Recruiting Aerosolized and Intravenous Colistin in Healthy Adults
Conditions: Pneumococcal Infection;   Pneumonia;   Pathogen Resistance
Intervention: Drug: Colistimethate sodium
5 Recruiting Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Conditions: HIV;   Pneumococcal Infections;   Pneumococcal Vaccines
Interventions: Biological: PCV-13;   Biological: PPSV-23
6 Not yet recruiting Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
Conditions: Pneumonia;   Pneumococcal Infections
Interventions: Drug: CAL02 Low-dose;   Drug: CAL02 High-dose;   Drug: Placebo
7 Recruiting A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
Condition: Pneumococcal Infections
Interventions: Biological: V114;   Biological: Prevnar 13™
8 Recruiting A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
Condition: Pneumococcal Infections
Interventions: Biological: V114 Formulation A;   Biological: V114 Formulation B;   Biological: Prevnar 13™
9 Recruiting A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
Condition: Pneumococcal Infections
Interventions: Biological: V114 Medium Dose;   Biological: V114 High Dose;   Biological: V114 Medium Dose with Alternative Carrier Protein;   Biological: V114 High Dose with Alternative Carrier Protein;   Biological: Prevnar 13™
10 Unknown  An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department
Condition: Pneumococcal Infections
11 Unknown  PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease
Conditions: Middle Ear Effusion;   Tympanic Membrane Perforation;   Acute Otitis Media;   Pneumococcal Infections
Intervention: Biological: 23 valent pneumococcal polysaccharide vaccine
12 Recruiting Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease
Conditions: Invasive Pneumococcal Infections;   Sickle Cells Disease
Interventions: Biological: Vaccination with the combined vaccine (Prevenar13 ®);   Biological: Vaccination with the polysaccharide vaccine (Pneumo 23 ®)
13 Recruiting Protection Against Pneumococcal Infection in Children With T1DM
Condition: Type 1 Diabetes Mellitus
Intervention: Biological: 13-valent pneumococcal conjugate vaccine (PCV13)
14 Recruiting Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD
Conditions: Infections, Pneumococcal;   Bowel Diseases, Inflammatory
Interventions: Biological: Prevenar 13;   Biological: Pneumo 23
15 Recruiting The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
Conditions: Rotavirus Infections;   Intestinal Bacteria Flora Disturbance;   Reaction - Vaccine Nos;   Tetanus;   Streptococcal Pneumonia
Intervention: Biological: Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine
16 Unknown  Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.
Conditions: Seizures;   Pneumococcal Meningitis
Interventions: Drug: Phenytoin;   Drug: placebo
17 Recruiting Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults
Condition: Splenectomized Patients
Intervention: Biological: Prime-boost pneumococcal immunization

Indicates status has not been verified in more than two years